Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CDC25A | P30304 | 3/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26980634 | 1.00 | NPC1L1 (0.51) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL27125991 | 1.00 | NPC1L1 (0.51) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL26120987 | 1.00 | NPC1L1 (0.51) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL26121915 | 0.93 | NPC1L1 (0.53) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL26121912 | 0.93 | NPC1L1 (0.53) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL26979040 | 0.93 | NPC1L1 (0.53) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6300889 | 0.88 | NPC1L1 (0.55) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL16163620 | 0.88 | NPC1L1 (0.55) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL9133868 | 0.88 | NPC1L1 (0.55) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6300887 | 0.88 | NPC1L1 (0.55) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002429-A1 | PRODRUG OF 5a-HYDROXY-6ß-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3ß-OL AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | DENDROGENIX (BE) | 2024-01-04 | — | — | US | disclosed |
| EP-4255441-A1 | PRODRUG OF 5a-HYDROXY-6ß-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3ß-OL AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | Dendrogenix (BE) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002429-A1 | PRODRUG OF 5a-HYDROXY-6ß-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3ß-OL AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | CYP7A1, CYP46A1, ABCB11 | NPC1L1 71/4885USP2 3588/4885LMNA 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.